Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Quantiscope
AddedFeb 17, 2024
UpdatedJun 18, 2026
Quantiscope

Quantiscope

Angel

QUANTiSCOPE: Streamlining drug discovery with easy-to-integrate automated image analysis tools.

Founded
2022
Overview
Compare
Fundraising
Employees
Website

Founded with the mission to enhance drug discovery, Quantiscope provides automated image analysis tools that seamlessly integrate into research processes. Their core product, the PhenotypIQ® enterprise platform, utilizes AI to convert microscopic images into quantifiable phenotypic data. This innovation supports researchers and regulators globally in developing more effective and safer therapies. Quantiscope focuses on the pharmaceutical and biotechnology markets, aiming to streamline and accelerate the drug discovery pipeline.

Quantiscope has garnered attention from notable figures in the biotech and AI sectors, attracting significant investment to fuel its growth. The company has achieved key milestones, including the successful deployment of PhenotypIQ® in various research institutions and pharmaceutical companies. By transforming image-based data into actionable insights, Quantiscope has made a substantial impact on the efficiency and accuracy of drug discovery, contributing to advancements in medical research and therapeutic development.

Quantiscope - Similar Companies

Biodock logo

Biodock

biodock.ai

PhenoVista Biosciences logo

PhenoVista Biosciences

phenovista.com

QbDVision logo

QbDVision

qbdvision.com

Modicus Prime logo

Modicus Prime

modicusprime.com

Singularity.AI logo

Singularity.AI

singularity.ai

Quantificare logo

Quantificare

quantificare.com

Quantivly logo

Quantivly

quantivly.com

Quantitative Insights logo

Quantitative Insights

Phronesis Artificial Intelligence logo

Phronesis Artificial Intelligence

phronesisai.com

ViQi logo

ViQi

viqiai.com

Omix.ai logo

Omix.ai

Scispot logo

Scispot

scispot.io

Cognaisent logo

Cognaisent

cognaisent.com

CytoTronics logo

CytoTronics

cytotronics.com

TandemAI logo

TandemAI

tandemai.com

Quantiscope - Quick Facts

Who are Quantiscope's competitors?

Companies similar to Quantiscope include Biodock, PhenoVista Biosciences, QbDVision and Modicus Prime.

When was Quantiscope founded?

Quantiscope was founded in 2022.

When was Quantiscope's last funding round?

Quantiscope's most recent funding round was for $5k (USD) in August 2022.

How much has Quantiscope raised to-date?

As of Aug 10, 2022, Quantiscope has raised a total of $5k (USD).

How many employees does Quantiscope have?

Quantiscope has 1 employee as of Feb 4, 2024.

Quantiscope - Classification

Ownership
  • Private Equity
  • Venture Capital
Technology
  • AI
  • Machine Learning
Geographic Exposure
  • Global
Model
  • Platform
Revenue
  • Recurring
  • Software
  • Subscription
Main Product
  • Drug Discovery
  • Image Analysis
Tags
  • Biotech
  • SaaS
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software